JAK2 Mutation Panel (Exon 12 - 15) Analysis

This Test is a molecular genetic test that detects mutations in the JAK2 gene, particularly in exons 12 to 15. These mutations are commonly associated with myeloproliferative neoplasms (MPNs), a group of blood disorders characterized by abnormal production of blood cells in the bone marrow.

The most common mutation, JAK2 V617F, along with exon 12 mutations, is frequently seen in conditions such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

The purpose of this test is to:

• Detect mutations in the JAK2 gene (Exon 12–15)
• Diagnose myeloproliferative neoplasms (MPNs)
• Differentiate between types of blood disorders
• Support treatment planning and disease monitoring

JAK2 MUTATION PANEL (EXON 12 - 15) ANALYSIS Test Purpose

The JAK2 Mutation Panel (Exon 12–15) Analysis is a molecular genetic test that looks for specific mutations in the JAK2 (Janus Kinase 2) gene, particularly across exons 12 to 15. JAK2 plays an important role in signaling pathways that regulate the production and development of blood cells.

JAK2 mutations are commonly associated with myeloproliferative neoplasms (MPNs), a group of blood disorders in which the bone marrow produces excessive numbers of one or more types of blood cells. The test can help support the evaluation of conditions such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

The analysis may be particularly useful when a person has unexplained abnormalities in blood counts, such as persistently elevated red blood cells, platelets, or white blood cells. The result is interpreted along with blood counts, clinical findings, and other laboratory or genetic investigations.

JAK2 MUTATION PANEL (EXON 12 - 15) ANALYSIS Test is Recommended for Individuals:

• Being evaluated for a suspected myeloproliferative neoplasm (MPN)
• With unexplained or persistent high platelet counts
• Being evaluated for polycythemia vera, essential thrombocythemia, or primary myelofibrosis
• With clinical findings suggesting a JAK2-associated blood disorder
• With abnormal blood cell production or unexplained changes in blood counts
• Requiring further molecular testing after routine blood investigations suggest an MPN
• With persistently elevated haemoglobin or hematocrit

FAQs

1. What is the JAK2 Mutation Panel (Exon 12–15) Analysis?
It is a molecular genetic test that analyses exons 12 to 15 of the JAK2 gene to identify mutations associated with certain myeloproliferative neoplasms.

2. Why is JAK2 mutation testing performed?
JAK2 mutation testing helps support the diagnosis of certain blood disorders, particularly polycythemia vera, essential thrombocythemia, and primary myelofibrosis. It is generally interpreted together with blood counts, symptoms, and other investigations.

3. Does a positive JAK2 mutation result confirm a blood cancer?
A positive JAK2 mutation can provide important evidence for a JAK2-associated myeloproliferative neoplasm, but the result alone does not establish a diagnosis. A healthcare professional will consider the genetic finding along with clinical history, blood counts, bone marrow findings, and other relevant tests.